Anodyne (US) acquired Pure Stride (US), expanding its foot health portfolio with podiatrist-designed orthotics. The acquisition was completed on February 5, 2026.

Acquirer:Anodyne
Target:Pure Stride
Deal value:Undisclosed
Type of deal:Asset acquisition
Closing date:February 5, 2026
Buy-side financial advisor:Three Sixty Seven Advisors
Sell-side financial advisor:Not disclosed

Anodyne acquired Pure Stride, a 10-year-old orthotic brand, to complement its existing therapeutic footwear portfolio. The deal aims to provide healthcare professionals and consumers with complete foot health solutions that integrate both footwear and orthotics.

Strategic Rationale

The acquisition enhances Anodyne's ability to offer comprehensive foot health products by incorporating Pure Stride’s range of over 20 podiatrist-designed orthotic styles, including full-length, three-quarter length, dress, kids', sport, court, golf, and Rx orthotics.

Financial Context

Pure Stride’s orthotic designs are known for their premium materials and thoughtful design elements such as antimicrobial top covers and anatomically positioned arch support. By integrating these products into its offerings, Anodyne aims to strengthen its market position in the therapeutic footwear sector.

Advisors

Anodyne was advised by Three Sixty Seven Advisors on this transaction.